Evidence map›Paper›PMID 25668003›Full record

ArticleBritish journal of cancer2015

Tailoring heated intraperitoneal mitomycin C for peritoneal metastases originating from colorectal carcinoma: a translational approach to improve survival.

R Kwakman, E M V de Cuba, J P de Winter, I H J T de Hingh, P M Delis-van Diemen, M Tijssen, M A Rooimans, O Krijgsman, B Carvalho, G J Peters and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

R KwakmanDepartment of Surgical Oncology, Cancer Center Amsterdam and VU University Medical Center, De Boelelaan 1117, Amsterdam 1081 HV, The Netherlands.
E M V de CubaDepartment of Surgical Oncology, Cancer Center Amsterdam and VU University Medical Center, De Boelelaan 1117, Amsterdam 1081 HV, The Netherlands.
J P de WinterDepartment of Clinical Genetics, Cancer Center Amsterdam and VU University Medical Center, De Boelelaan 1117, Amsterdam 1081 HV, The Netherlands.
I H J T de HinghDepartment of Surgery, Catharina Ziekenhuis Eindhoven, Eindhoven, The Netherlands.
P M Delis-van DiemenDepartment of Pathology and Tumour Profiling Unit, Cancer Center Amsterdam and VU University Medical Center, De Boelelaan 1117, Amsterdam 1081 HV, The Netherlands.
M TijssenDepartment of Pathology and Tumour Profiling Unit, Cancer Center Amsterdam and VU University Medical Center, De Boelelaan 1117, Amsterdam 1081 HV, The Netherlands.
M A RooimansDepartment of Clinical Genetics, Cancer Center Amsterdam and VU University Medical Center, De Boelelaan 1117, Amsterdam 1081 HV, The Netherlands.
O KrijgsmanDepartment of Pathology and Tumour Profiling Unit, Cancer Center Amsterdam and VU University Medical Center, De Boelelaan 1117, Amsterdam 1081 HV, The Netherlands.
B CarvalhoDepartment of Pathology and Tumour Profiling Unit, Cancer Center Amsterdam and VU University Medical Center, De Boelelaan 1117, Amsterdam 1081 HV, The Netherlands.
G J PetersDepartment of Oncology, Cancer Center Amsterdam and VU University Medical Center, De Boelelaan 1117, Amsterdam 1081 HV, The Netherlands.
H J BonjerDepartment of Surgical Oncology, Cancer Center Amsterdam and VU University Medical Center, De Boelelaan 1117, Amsterdam 1081 HV, The Netherlands.
G A MeijerDepartment of Pathology and Tumour Profiling Unit, Cancer Center Amsterdam and VU University Medical Center, De Boelelaan 1117, Amsterdam 1081 HV, The Netherlands.
E A Te VeldeDepartment of Surgical Oncology, Cancer Center Amsterdam and VU University Medical Center, De Boelelaan 1117, Amsterdam 1081 HV, The Netherlands.
Amsterdam UMC Location VUmc · NLCatharina Ziekenhuis · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with peritoneal metastases (PMs) originating from colorectal carcinoma (CRC) are curatively treated by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) with mitomycin C (MMC). We aim to improve patient selection for HIPEC by predicting MMC sensitivity.

methodsThe MMC sensitivity was determined for 12 CRC cell lines and correlated to mRNA expression of 37 genes related to the Fanconi anaemia (FA)-BRCA pathway, ATM-ATR pathway and enzymatic activation of MMC. Functionality of the FA-BRCA pathway in cell lines was assessed using a chromosomal breakage assay and western blot for key protein FANCD2. Bloom syndrome protein (BLM) was further analysed by staining for the corresponding protein with immunohistochemistry (IHC) on both CRC cell lines (n=12) and patient material (n=20).

resultsHigh sensitivity correlated with a low BLM (P=0.01) and BRCA2 (P=0.02) at mRNA expression level. However, FA-BRCA pathway functionality demonstrated no correlation to MMC sensitivity. In cell lines, weak intensity staining of BLM by IHC correlated to high sensitivity (P=0.04) to MMC. Low BLM protein expression was significantly associated with an improved survival in patients after CRS and HIPEC (P=0.04).

conclusionsLow BLM levels are associated with high MMC sensitivity and an improved survival after HIPEC.

Indexed as

Antibiotics, AntineoplasticBiomarkers, TumorCaco-2 CellsCell Line, TumorColorectal NeoplasmsFanconi Anemia Complementation Group D2 ProteinGene Expression Regulation, NeoplasticHCT116 CellsHT29 CellsHumansHyperthermia, InducedMitomycinPeritoneal NeoplasmsRecQ HelicasesSignal TransductionSurvival AnalysisAntibiotics, AntineoplasticBiomarkers, TumorBloom syndrome proteinFANCD2 protein, humanFanconi Anemia Complementation Group D2 ProteinMitomycinRecQ Helicases

Identifiers

PMID25668003
PMCPMC4453952
OpenAlexW1989884240

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.